Biochemotherapy in Patients with Metastatic Anorectal Mucosal Melanoma

Kevin B. Kim, Angela M. Sanguino, Cynthia Hodges, Nicholas E. Papadopoulos, Omar Eton, Luis H. Camacho, Lyle D. Broemeling, Marcella M. Johnson, Matthew Ballo, Merrick I. Ross, Jeffrey E. Gershenwald, Jeffrey E. Lee, Paul F. Mansfield, Victor G. Prieto, Agop Y. Bedikian

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

BACKGROUND. Patients with metastatic anorectal melanoma generally have an unfavorable prognosis, but no effective systemic therapy has been reported. METHODS. The authors retrospectively evaluated the medical records of all patients with metastatic anorectal melanoma treated with biochemotherapy between January 1991 and December 2001 at the University of Texas M. D. Anderson Cancer Center (Houston, TX). RESULTS. The search yielded 18 patients. Of these patients, 14 had undergone treatment with cisplatin (CDDP), vinblastine (VB), dacarbazine (DTIC), interferon alpha-2b (IFN), and interleukin 2 (IL-2); 2 had undergone treatment with CDDP, VB, DTIC, and IFN; 1 had undergone treatment with CDDP, IFN, and IL-2; and 1 had undergone treatment with CDDP, VB, temozolomide, IFN, and IL-2. All IL-2 treatments were administered intravenously. The median follow-up time was 12.2 months (range, 3.5-43.7 months). Eight patients (44%) had major responses, including two (11%) complete responses (CRs). Three patients were lost to follow-up evaluation after the completion of treatment. The median time to progression among the 15 remaining patients was 6.2 months. Four patients, including 1 with a CR, were alive at their last documented follow-up visits (survival: 14.0, 20.7, 31.3, and 43.7 months, respectively). The median overall survival was 12.2 months. Among 13 patients who received biochemotherapy as first-line systemic therapy, 6 patients (46%) had major responses, including two (15%) CRs. The median time to progression for this group was 6.2 months, and the median overall survival was 12.9 months. CONCLUSIONS. Biochemotherapy had substantial activity against metastatic anorectal melanoma and should be considered for use in the treatment of metastatic disease from primary anorectal melanoma.

Original languageEnglish (US)
Pages (from-to)1478-1483
Number of pages6
JournalCancer
Volume100
Issue number7
DOIs
StatePublished - Apr 1 2004

Fingerprint

Melanoma
Dacarbazine
Interleukin-2
Vinblastine
Therapeutics
interferon alfa-2b
temozolomide
Survival
Rectal Diseases
Lost to Follow-Up
Interleukin-1
Cisplatin
Medical Records

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, K. B., Sanguino, A. M., Hodges, C., Papadopoulos, N. E., Eton, O., Camacho, L. H., ... Bedikian, A. Y. (2004). Biochemotherapy in Patients with Metastatic Anorectal Mucosal Melanoma. Cancer, 100(7), 1478-1483. https://doi.org/10.1002/cncr.20113

Biochemotherapy in Patients with Metastatic Anorectal Mucosal Melanoma. / Kim, Kevin B.; Sanguino, Angela M.; Hodges, Cynthia; Papadopoulos, Nicholas E.; Eton, Omar; Camacho, Luis H.; Broemeling, Lyle D.; Johnson, Marcella M.; Ballo, Matthew; Ross, Merrick I.; Gershenwald, Jeffrey E.; Lee, Jeffrey E.; Mansfield, Paul F.; Prieto, Victor G.; Bedikian, Agop Y.

In: Cancer, Vol. 100, No. 7, 01.04.2004, p. 1478-1483.

Research output: Contribution to journalArticle

Kim, KB, Sanguino, AM, Hodges, C, Papadopoulos, NE, Eton, O, Camacho, LH, Broemeling, LD, Johnson, MM, Ballo, M, Ross, MI, Gershenwald, JE, Lee, JE, Mansfield, PF, Prieto, VG & Bedikian, AY 2004, 'Biochemotherapy in Patients with Metastatic Anorectal Mucosal Melanoma', Cancer, vol. 100, no. 7, pp. 1478-1483. https://doi.org/10.1002/cncr.20113
Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH et al. Biochemotherapy in Patients with Metastatic Anorectal Mucosal Melanoma. Cancer. 2004 Apr 1;100(7):1478-1483. https://doi.org/10.1002/cncr.20113
Kim, Kevin B. ; Sanguino, Angela M. ; Hodges, Cynthia ; Papadopoulos, Nicholas E. ; Eton, Omar ; Camacho, Luis H. ; Broemeling, Lyle D. ; Johnson, Marcella M. ; Ballo, Matthew ; Ross, Merrick I. ; Gershenwald, Jeffrey E. ; Lee, Jeffrey E. ; Mansfield, Paul F. ; Prieto, Victor G. ; Bedikian, Agop Y. / Biochemotherapy in Patients with Metastatic Anorectal Mucosal Melanoma. In: Cancer. 2004 ; Vol. 100, No. 7. pp. 1478-1483.
@article{b9e8f3923956408ab87cc92c0920782e,
title = "Biochemotherapy in Patients with Metastatic Anorectal Mucosal Melanoma",
abstract = "BACKGROUND. Patients with metastatic anorectal melanoma generally have an unfavorable prognosis, but no effective systemic therapy has been reported. METHODS. The authors retrospectively evaluated the medical records of all patients with metastatic anorectal melanoma treated with biochemotherapy between January 1991 and December 2001 at the University of Texas M. D. Anderson Cancer Center (Houston, TX). RESULTS. The search yielded 18 patients. Of these patients, 14 had undergone treatment with cisplatin (CDDP), vinblastine (VB), dacarbazine (DTIC), interferon alpha-2b (IFN), and interleukin 2 (IL-2); 2 had undergone treatment with CDDP, VB, DTIC, and IFN; 1 had undergone treatment with CDDP, IFN, and IL-2; and 1 had undergone treatment with CDDP, VB, temozolomide, IFN, and IL-2. All IL-2 treatments were administered intravenously. The median follow-up time was 12.2 months (range, 3.5-43.7 months). Eight patients (44{\%}) had major responses, including two (11{\%}) complete responses (CRs). Three patients were lost to follow-up evaluation after the completion of treatment. The median time to progression among the 15 remaining patients was 6.2 months. Four patients, including 1 with a CR, were alive at their last documented follow-up visits (survival: 14.0, 20.7, 31.3, and 43.7 months, respectively). The median overall survival was 12.2 months. Among 13 patients who received biochemotherapy as first-line systemic therapy, 6 patients (46{\%}) had major responses, including two (15{\%}) CRs. The median time to progression for this group was 6.2 months, and the median overall survival was 12.9 months. CONCLUSIONS. Biochemotherapy had substantial activity against metastatic anorectal melanoma and should be considered for use in the treatment of metastatic disease from primary anorectal melanoma.",
author = "Kim, {Kevin B.} and Sanguino, {Angela M.} and Cynthia Hodges and Papadopoulos, {Nicholas E.} and Omar Eton and Camacho, {Luis H.} and Broemeling, {Lyle D.} and Johnson, {Marcella M.} and Matthew Ballo and Ross, {Merrick I.} and Gershenwald, {Jeffrey E.} and Lee, {Jeffrey E.} and Mansfield, {Paul F.} and Prieto, {Victor G.} and Bedikian, {Agop Y.}",
year = "2004",
month = "4",
day = "1",
doi = "10.1002/cncr.20113",
language = "English (US)",
volume = "100",
pages = "1478--1483",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Biochemotherapy in Patients with Metastatic Anorectal Mucosal Melanoma

AU - Kim, Kevin B.

AU - Sanguino, Angela M.

AU - Hodges, Cynthia

AU - Papadopoulos, Nicholas E.

AU - Eton, Omar

AU - Camacho, Luis H.

AU - Broemeling, Lyle D.

AU - Johnson, Marcella M.

AU - Ballo, Matthew

AU - Ross, Merrick I.

AU - Gershenwald, Jeffrey E.

AU - Lee, Jeffrey E.

AU - Mansfield, Paul F.

AU - Prieto, Victor G.

AU - Bedikian, Agop Y.

PY - 2004/4/1

Y1 - 2004/4/1

N2 - BACKGROUND. Patients with metastatic anorectal melanoma generally have an unfavorable prognosis, but no effective systemic therapy has been reported. METHODS. The authors retrospectively evaluated the medical records of all patients with metastatic anorectal melanoma treated with biochemotherapy between January 1991 and December 2001 at the University of Texas M. D. Anderson Cancer Center (Houston, TX). RESULTS. The search yielded 18 patients. Of these patients, 14 had undergone treatment with cisplatin (CDDP), vinblastine (VB), dacarbazine (DTIC), interferon alpha-2b (IFN), and interleukin 2 (IL-2); 2 had undergone treatment with CDDP, VB, DTIC, and IFN; 1 had undergone treatment with CDDP, IFN, and IL-2; and 1 had undergone treatment with CDDP, VB, temozolomide, IFN, and IL-2. All IL-2 treatments were administered intravenously. The median follow-up time was 12.2 months (range, 3.5-43.7 months). Eight patients (44%) had major responses, including two (11%) complete responses (CRs). Three patients were lost to follow-up evaluation after the completion of treatment. The median time to progression among the 15 remaining patients was 6.2 months. Four patients, including 1 with a CR, were alive at their last documented follow-up visits (survival: 14.0, 20.7, 31.3, and 43.7 months, respectively). The median overall survival was 12.2 months. Among 13 patients who received biochemotherapy as first-line systemic therapy, 6 patients (46%) had major responses, including two (15%) CRs. The median time to progression for this group was 6.2 months, and the median overall survival was 12.9 months. CONCLUSIONS. Biochemotherapy had substantial activity against metastatic anorectal melanoma and should be considered for use in the treatment of metastatic disease from primary anorectal melanoma.

AB - BACKGROUND. Patients with metastatic anorectal melanoma generally have an unfavorable prognosis, but no effective systemic therapy has been reported. METHODS. The authors retrospectively evaluated the medical records of all patients with metastatic anorectal melanoma treated with biochemotherapy between January 1991 and December 2001 at the University of Texas M. D. Anderson Cancer Center (Houston, TX). RESULTS. The search yielded 18 patients. Of these patients, 14 had undergone treatment with cisplatin (CDDP), vinblastine (VB), dacarbazine (DTIC), interferon alpha-2b (IFN), and interleukin 2 (IL-2); 2 had undergone treatment with CDDP, VB, DTIC, and IFN; 1 had undergone treatment with CDDP, IFN, and IL-2; and 1 had undergone treatment with CDDP, VB, temozolomide, IFN, and IL-2. All IL-2 treatments were administered intravenously. The median follow-up time was 12.2 months (range, 3.5-43.7 months). Eight patients (44%) had major responses, including two (11%) complete responses (CRs). Three patients were lost to follow-up evaluation after the completion of treatment. The median time to progression among the 15 remaining patients was 6.2 months. Four patients, including 1 with a CR, were alive at their last documented follow-up visits (survival: 14.0, 20.7, 31.3, and 43.7 months, respectively). The median overall survival was 12.2 months. Among 13 patients who received biochemotherapy as first-line systemic therapy, 6 patients (46%) had major responses, including two (15%) CRs. The median time to progression for this group was 6.2 months, and the median overall survival was 12.9 months. CONCLUSIONS. Biochemotherapy had substantial activity against metastatic anorectal melanoma and should be considered for use in the treatment of metastatic disease from primary anorectal melanoma.

UR - http://www.scopus.com/inward/record.url?scp=12144291500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144291500&partnerID=8YFLogxK

U2 - 10.1002/cncr.20113

DO - 10.1002/cncr.20113

M3 - Article

C2 - 15042682

AN - SCOPUS:12144291500

VL - 100

SP - 1478

EP - 1483

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -